Valsartan

缬沙坦

Report date: 2022/08/16 20:00:19
NME

Base Information

Drug NameValsartan
Drug Alias NameValsartanum代文ValsMitenNisis +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1
Therapy Area/IndicationsMetabolic SyndromeEssential HypertensionHypertension +[16] 
Global Approved IndicationsHypertensionHeart FailurePostmyocardial Infarction Syndrome
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1996/12/23
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgUniversity Of WashingtonLivzon(Group) Pharmaceutical Factory +[5] 
Inactive CompaniesCarelon ResearchCarmel Biosciences IncLg Chemical Ltd +[8] 
Active IndicationsEssential HypertensionHypertensionVentricular Dysfunction, Right +[4] 
Inactive IndicationsMetabolic SyndromeAtherosclerosisVentricular Dysfunction, Left +[12] 

Other Information

ATC CodeC09CA03
Related LinksWikipediaDrugBankKEGG